Nanotubes Connect CD4+ T Cells to Airway Smooth Muscle Cells: Novel Mechanism of T Cell Survival.

Related Articles

Nanotubes Connect CD4+ T Cells to Airway Smooth Muscle Cells: Novel Mechanism of T Cell Survival.

J Immunol. 2015 May 1;

Authors: Al Heialy S, Zeroual M, Farahnak S, McGovern T, Risse PA, Novali M, Lauzon AM, Roman HN, Martin JG

Abstract
Contact between airway smooth muscle (ASM) cells and activated CD4(+) T cells, a key interaction in diseases such as asthma, triggers ASM cell proliferation and enhances T cell survival. We hypothesized that direct contact between ASM and CD4(+) T cells facilitated the transfer of anti-apoptotic proteins via nanotubes, resulting in increased survival of activated CD4(+) T cells. CD4(+) T cells, isolated from PBMCs of healthy subjects, when activated and cocultured with ASM cells for 24 h, formed nanotubes that were visualized by immunofluorescence and atomic force microscopy. Cell-to-cell transfer of the fluorescent dye calcein-AM confirmed cytoplasmic communication via nanotubes. Immunoreactive B cell lymphoma 2 (Bcl-2) and induced myeloid leukemia cell differentiation protein (Mcl-1), two major anti-apoptotic proteins, were present within the nanotubes. Downregulation of Mcl-1 by small interfering RNA in ASM cells significantly increased T cell apoptosis, whereas downregulation of Bcl-2 had no effect. Transfer of GFP-tagged Mcl-1 from ASM cells to CD4(+) T cells via the nanotubes confirmed directionality of transfer. In conclusion, activated T cells communicate with ASM cells via nanotube formation. Direct transfer of Mcl-1 from ASM to CD(+) T cells via nanotubes is involved in T cell survival. This study provides a novel mechanism of survival of CD4(+) T cells that is dependent on interaction with a structural cell.

PMID: 25934863 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

Concomitant MAZE procedure during cardiac surgical procedures, is there any survival advantage in conversion to sinus rhythm?

Related Articles

Concomitant MAZE procedure during cardiac surgical procedures, is there any survival advantage in conversion to sinus rhythm?

Minerva Cardioangiol. 2014 Oct 30;

Authors: Neragi-Miandoab S, Skripochnik E, Michler RE, Friedman P, D’alessandro DA

Abstract
BACKGROUND: The MAZE procedure, or concomitant intraoperative ablation, is an effective technique to restore long–term sinus rhythm (SR). The survival benefit of conversion to SR has been questioned recently.
METHODS AND RESULTS: We retrospectively evaluated the conversion rate to SR and its correlation with long–term survival in 209 patients with chronic AF, who had a MAZE procedure during cardiac surgical procedures between the years 2006 and 2011 at our institution. The mean age was 67.2 ± 12.0 years and 52.2% were female (n=109). Perioperative mortality was 5.74% (n=12). In univariate analysis, significant risk factors for perioperative mortality were age (p=0.0033), duration of perfusion time (p=0.0093), elevated creatinine (?1.6 mg/dL, p=.02), and cross clamp time (p=0.016). In multivariate analysis age (HR 2.97) and duration of perfusion time (HR 1.48) were the only independent predictors of perioperative mortality. The overall one and five–year survival rates were 88%±2.2%, and 76%±3.3%, respectively. The one and five–year survival rates for patients who converted and were in sinus rhythm (SR) upon discharge (n=154) were 88%±2.6% and 80%±3.5%, respectively. While the one and five–year survival rates for patients who were still in AF upon discharge (n=55) were 94%±3% and 82%±6.6%, respectively, this survival difference was not statistically significant (p=0.24). Significant risk factors for long–term mortality included DM (p=0.023), preoperative MI (p=0.043), preoperative renal insufficiency (creatinine, ?1.6 mg/dL, p=0.02) and asthma/COPD (p=0.040). In multivariate analysis, age (HR 1.048) and preoperative MI (HR 1.948) were the only independent predictors of long–term mortality.
CONCLUSION: The surgical MAZE procedure has a high conversion rate, however, our data did not show improved survival in patients who converted to SR prior to discharge.

PMID: 25358018 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

Allergy Survival Guide for the Holidays – Fox News


Newnan Times-Herald

Allergy Survival Guide for the Holidays
Fox News
There is a distinct possibility that holidays may not bring all cheer, especially if you or family members have allergies and/or asthma. Exposure to scented candles, incense, potpourri, air fresheners, “fireplace” smoke and even
Boy creates perfect hypoallergenic pet for grandmotherNewnan Times-Herald

all 16 news articles »

View full post on asthma – Google News

Smoking ban linked to survival, drop in kids’ asthma – USA Today


Scotland Courier

Smoking ban linked to survival, drop in kids' asthma
USA Today
By Carolyn Kaster, AP By Liz Szabo, USA TODAY Smoking bans can lead to major improvements in childhood asthma, and potentially save lives, a new study shows
Scottish smoking ban cuts childhood asthma attacksReuters
Smoking bans help curb kids' severe asthma attacksThe Associated Press
Scottish kids' asthma declined after smoking banScience News
Bloomberg –MedPage Today –MSN Health & Fitness
all 64 news articles »

View full post on asthma – Google News

NIH-Funded Study Finds Early HAART during TB Treatment Boosts Survival Rate in People Co-Infected with HIV and TB

A clinical trial in Cambodia has found it possible to prolong the survival of untreated HIV-infected adults with very weak immune systems and newly diagnosed tuberculosis (TB) by starting anti-HIV therapy two weeks after beginning TB treatment, rather than waiting eight weeks, as has been standard. This finding by scientists co-funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the French National Agency for Research on AIDS and Viral Hepatitis, brings physicians closer to optimizing the treatment of severely immunosuppressed individuals with HIV-TB co-infection. The findings were presented today at the XVIII International AIDS Conference in Vienna by principal investigators Francois-Xavier Blanc, M.D., Anne E. Goldfeld, M.D., and Sok Thim, M.D.

View full post on National Institutes of Health (NIH) News Releases